系统性硬化症肥胖患者的病死亡率:一项比较研究
Lucile Grange1, Benjamin Chaigne2, Marion Casadevall2
1Service de médecine interne, Centre de référence maladies systémiques autoimmunes et autoinflammatoires rares d'Île-de-France de l'Est et de l'Ouest, hôpital Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France; AP-HP-CUP, hôpital Cochin, Université Paris Cité, 75014 Paris, France; Service de médecine interne, CHU de Saint-Étienne, Saint-Étienne, France.
概括
与非肥胖的SSc患者相比,患有系统性硬化症 (SSc) 的肥胖患者心血管风险更高,但器官损伤和死亡率相似. 这项研究强调了肥胖SSc个体临床特征和结果的关键差异.
科学领域:
- 类风湿病学 类风湿病学
- 心脏病学 心脏病学
- 肥胖医学 肥胖医学
背景情况:
- 系统性硬化症 (SSc) 和肥胖的患病率正在上升.
- 关于肥胖的SSc患者的数据有限.
- 这项研究解决了有关肥胖SSc患者的知识差距.
研究的目的:
- 评估SSc患者中肥胖的流行率.
- 评估肥胖SSc患者的临床特征.
- 确定SSc.中肥胖的长期后果.
主要方法:
- 追溯性比较研究. 追溯性比较研究.
- 从科大学医院 (2000-2019) 收集的数据.
- 包括911名SSc患者,其中90人被确定为肥胖.
主要成果:
- 肥胖的SSc患者 (9.9%) 的心血管风险因素较高.
- 肥胖患者显示更低的修饰罗丹皮肤得分 (mRSS) 和较少的化.
- 肥胖和非肥胖的SSc患者之间没有观察到器官参与或30年生存率的显著差异.
结论:
- 肥胖的SSc患者表现出明显的特征,包括心血管风险增加和皮肤干扰减少.
- 在SSc中,肥胖似乎没有显著影响器官损伤或死亡率.
- 需要进一步研究在肥胖的SSc患者中管理心血管风险.
相关概念视频
Obesity
1.6K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Drug Dosing: Obese Patients
372
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
372
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
445
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
445
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
330
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
330


